Compare AbbVie Inc (ABBV) vs iShares Core S&P 500 ETF (IVV) Price & Performance

AbbVie IncTrade

iShares Core S&P 500 ETFTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs iShares Core S&P 500 ETF — how do they compare? AbbVie Inc trades at $249.43 (market cap $441.94B), while iShares Core S&P 500 ETF trades at $776.09. The key difference: AbbVie Inc pays a 2.77% dividend while iShares Core S&P 500 ETF pays none, and iShares Core S&P 500 ETF is trading nearer its 52-week high, AbbVie Inc nearer its low. Which is the better fit depends on your goals.

	ABBV	IVV
Market Cap	$441.94B	—
Sector	Health	Broad Market / Factor
52-Week High	$263.58	$776.81
52-Week Low	$197.38	$634.93
Enterprise Value	$506.19B	—
Dividend Yield	2.77%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.

Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.

iShares Core S&P 500 ETF

IVV, tracking the S&P 500, trades at $776.38, down slightly by 0.04% amid broader market caution ahead of inflation data. The ETF shows a bullish technical signal with moving averages supporting upside, but oscillators are neutral and RSI levels indicate overbought conditions. Recent news highlights institutional interest, with First Bank & Trust increasing its stake, while JPMorgan raised its S&P 500 target to 8,000 for 2026, citing strong earnings and AI-driven growth (JPMorgan report, August 10, 2026).

Outlook remains positive due to robust corporate earnings and AI investments, but risks include high valuations and potential pullbacks from overbought levels. Investors should weigh the ETF's diversification benefits against market volatility and economic data sensitivity.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ABBV

Fidelity Dividend ETF's payout is safe but not ideal for steady income due to variable quarterly dividends.24/7 Wall Street · 1 day agoNeutral Two Dividend Aristocrats outperformed the market while two lagged; three new picks show promising dividend growth.24/7 Wall Street · 2 days agoNeutral Healthcare sector leads S&P 500 gains over 3 months with key pharma stocks showing strong innovation and income potential.24/7 Wall Street · 2 days agoBullish View details →

IVV

WisdomTree U.S. Total Dividend ETF (DTD) rated 'hold' for balanced factors but overlaps 57% with S&P 500 ETFs.Seeking Alpha · 1 day agoNeutral Main Sector Rotation ETF (SECT) gets Hold rating due to weak performance versus IVV.Seeking Alpha · 4 days agoNeutral View details →

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

About iShares Core S&P 500 ETF

IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.